Pivotal Bioventure Partners China
Sequoia leads $150m Series B for China's Visen Pharma
China’s Visen Pharmaceuticals, a drug developer targeting glandular conditions such as dwarfism and growth deficiency has raised a $150 million Series B round led by Sequoia Capital China.
Nan Fung, Pivotal China lead $80m round for Oncologie
Oncologie, a cancer drug developer with bases in Shanghai and Boston, has secured $80 million in Series B funding led by Nan Fung Life Sciences and Pivotal Bioventure Partners China.
China biotech: Finding the formula
An eruption of investment and company creation in Chinese biotech has signaled the dawn of a raw but promising market. First-movers must negotiate immediate pitfalls while targeting long-term upside
Pivotal China seeds Sino-US cancer drug developer
Pivotal BioVenture Partners China, an investment platform of Hong Kong conglomerate Nan Fung Group, has led a $16.5 million seed round for Sino-US cancer drug developer Oncologie.
Fund focus: Pivotal’s urge to incubate
Nan Fung Group has established Pivotal Bioventure Partners China to build a concentrated portfolio of high-quality life science assets and nurture them from inception to exit